Investor Presentation

Improving on Historical Growth M&A Snapshot 2014-2020 Acquisition year revenue (pro forma) "First full year" revenue growth JUNE 2014 Refine TECHNOLOGY $10.6M 48% Filtration APRIL 2016 * Excluding $4M in sales to Repligen. ** First full year of Repligen ownership, pro forma ATOLL convenience in bioscience $4.6M 26% Chromatography DEC. 2016 TANGENX $5.8M 37% Filtration AUG. 2017 SPECTRUM LABS.COM $37M* 24% Filtration MAY 2019 C TECHNOLOGIES, INC. Flow VPE HE $25.6M RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING 30% Process Analytics 2020 ARTESYN Engineered BIO-PRODUCTION Technology NMS Molding REPLIGEN Chockgraphy Syn ARTS 229 REPLIGEN >15% Systems/Fluid Management Ⓡ 13

View entire presentation